Preparing your experience...
Effective Date: February 24, 2026
Last Updated: March 2, 2026
Your medical provider may recommend compounded semaglutide based on a medical review. Compounded drugs are not FDA approved and are not evaluated for safety, effectiveness, or quality standards. This document is a summary of product information and does NOT have all possible information and potential side effects of the product. This is not medical advice and does not substitute advice from your health care provider.
Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review. Your provider, via Hume Care, may recommend certain doses of compounded semaglutide based on your medical evaluation.
Compounded semaglutide is an injectable prescription medicine that may help adults and adolescents with obesity and excess weight (overweight) - who may also have weight-related medical problems - lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.
Compounded semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of 27 kg/m² or higher.
Compounded semaglutide should not be used with other semaglutide-containing products or any other GLP-1/GIP receptor agonist medicines. It is not known if compounded semaglutide is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products. It is not known if compounded semaglutide can be used in people who have had pancreatitis. It is not known if compounded semaglutide is safe and effective for use in children under 18 years of age.
At lower (micro) doses, compounded semaglutide may also be beneficial for patients who:
Warning: Risk of Thyroid C-Cell Tumors
In studies with mice and rats, semaglutide caused thyroid tumors, including thyroid cancer. It is not known if compounded semaglutide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use compounded semaglutide if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Compounded semaglutide should not be used in combination with other semaglutide-containing products or any other GLP-1/GIP receptor agonist medicines.
The safety and efficacy of coadministration with other products for weight loss have not been established.
Compounded semaglutide has not been studied in patients with a history of pancreatitis.
Note: Compounded medications are not FDA approved and do not have indications for treatment as an FDA approved medication would.
Do not use compounded semaglutide if:
You can take compounded semaglutide with or without food. The pre-filled vial is self-administered with a needle and syringe as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your provider, via Hume Care, will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking compounded semaglutide as prescribed without discussing with your provider first.
Compounded semaglutide has certain drug interactions. It's important to tell your provider, via Hume Care, all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
Some medications to watch out for include:
It's important to share your entire medical history with your provider, via Hume Care. In particular, tell your provider if you have a past history of:
Tell your provider, via Hume Care, if you are pregnant, planning to become pregnant, or breastfeeding.
If you are pregnant: Compounded semaglutide should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to compounded semaglutide during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
If you are a female or male of reproductive potential: Discontinue compounded semaglutide at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.
If you are breastfeeding: Compounded semaglutide was found in the milk of lactating rats. Tell your provider, via Hume Care, if you are breastfeeding before you start compounded semaglutide. At this time, we do not recommend taking compounded semaglutide if you are breastfeeding or bottle-feeding with breastmilk.
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
The most common side effects are typically mild and usually resolve after the first several weeks of treatment. These can include nausea, vomiting, diarrhea, constipation, abdominal pain, upset stomach, abdominal distension, reflux, headache, fatigue, and dizziness. Swelling, redness, and itchiness at the injection site may occur. The FDA has issued its most serious warning (called a BOXED WARNING) that GLP-1s may be associated with a type of thyroid cancer called medullary thyroid carcinoma. So far, this side effect has primarily been seen in laboratory studies using rodents, so the risk to humans has not been determined.
Side Effects
Nausea, vomiting, stomach upset, diarrhea, tiredness, dizziness, or constipation may occur. Nausea usually lessens as you continue to use semaglutide. If any of these effects last or get worse, tell your provider or pharmacist promptly. Remember that this medication has been prescribed because your provider has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Vomiting/diarrhea that doesn't stop may result in dehydration. Contact your provider, via Hume Care, promptly if you notice any symptoms of dehydration, such as unusual dry mouth/thirst or dizziness/lightheadedness.
Tell your provider, via Hume Care, right away if you have any serious side effects, including: signs of kidney problems (such as change in the amount of urine), vision changes (such as decreased/blurred vision), fast heartbeat, mental/mood changes (such as depression, thoughts of suicide), signs of low blood sugar (sudden sweating, shaking, fast heartbeat, hunger, blurred vision, dizziness, tingling hands/feet).
Get medical help right away if you have any very serious side effects, including: signs of pancreas or gallbladder disease (such as nausea/vomiting that doesn't stop, severe stomach/abdominal pain). A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your provider or pharmacist. In the US - Call your provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.
WARNING: This medication has been found to cause a certain type of thyroid tumor (thyroid C-cell tumors) in rats and mice. It is unknown if this medication can cause similar tumors in humans. Talk with your provider about the benefits and risks of treatment with this medication. This medication should not be used by people with a personal/family history of a certain type of cancer (medullary thyroid carcinoma) or by people with a certain inherited disease (Multiple Endocrine Neoplasia syndrome type 2 or MEN 2). While using this medication, tell your provider, via Hume Care, right away if you notice any signs or symptoms of thyroid tumors, including unusual growth or lump in the neck, difficulty swallowing, shortness of breath, or unusual/lasting hoarseness.
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
These serious side effects can occur with compounded semaglutide. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.
Thyroid C-Cell Tumors: In mice and rats, semaglutide caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether compounded semaglutide causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza® and Saxenda®) after the drug was put on the market. Compounded semaglutide is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Acute Gallbladder Disease: Compounded semaglutide may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider, via Hume Care, right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Low Blood Sugar (Hypoglycemia): Compounded semaglutide may lower blood glucose. It can cause low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Acute Kidney Injury: In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.
Serious Allergic Reactions: Stop using compounded semaglutide right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: If you have type 2 diabetes, tell your provider, via Hume Care, right away if you experience changes in vision.
Increase in Heart Rate: Tell your provider, via Hume Care, right away if you have a racing heartbeat while at rest.
Suicidal Behavior and Ideation: You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your provider, via Hume Care, right away if you have any mental changes that are new, worse, or worry you.
Never Share a Vial/Needle/Syringe: Sharing poses a risk of infection.
If you have any current/recent prescriptions for either compounded or brand name weight loss medications, do not take both medications. You will be asked to provide evidence of the current/recent prescription including dose specifics. Taking two or more GLP-1/GIP medications at the same time increases the risk of potentially serious side effects. Notify your provider, via Hume Care, immediately if you have any current or previous prescriptions for compounded or brand name weight loss medications.
Failure to fully disclose your medical history to your provider may result in serious side effects, including death.
Your provider, via Hume Care, will direct you to instructions on how to administer your GLP-1 therapy.
Tell your provider, via Hume Care, if you are taking medicines to treat diabetes including insulin or sulfonylureas which could increase your risk of low blood sugar. Talk to your provider about low blood sugar levels and how to manage them.
If you take birth control pills by mouth, talk to your provider, via Hume Care, before you use compounded semaglutide. Birth control pills may not work as well while using compounded semaglutide. Your provider may recommend another type of birth control for 4 weeks after you start compounded semaglutide and for 4 weeks after each increase in your dose of compounded semaglutide.
Review these questions with your provider, via Hume Care:
Your medical provider may recommend compounded tirzepatide based on a medical review. Compounded drugs are not FDA approved and are not evaluated for safety, effectiveness, or quality standards. This document is a summary of product information and does NOT have all possible information and potential side effects of the product. This is not medical advice and does not substitute advice from your health care provider.
Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review. Your provider, via Hume Care, may recommend certain doses of compounded tirzepatide based on your medical evaluation.
Compounded tirzepatide is an injectable prescription medicine that may help adults and adolescents with obesity and excess weight (overweight) - who may also have weight-related medical problems - lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Compounded tirzepatide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of 27 kg/m² or higher.
Compounded tirzepatide should not be used with other tirzepatide-containing products or any other GLP-1/GIP receptor agonist medicines. It is not known if compounded tirzepatide is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products. It is not known if compounded tirzepatide can be used in people who have had pancreatitis. It is not known if compounded tirzepatide is safe and effective for use in children under 18 years of age.
At lower (micro) doses, compounded tirzepatide may also be beneficial for patients who:
Warning: Risk of Thyroid C-Cell Tumors
In studies with mice and rats, tirzepatide caused thyroid tumors, including thyroid cancer. It is not known if compounded tirzepatide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use compounded tirzepatide if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Compounded tirzepatide should not be used in combination with other tirzepatide-containing products or any other GLP-1/GIP receptor agonist medicines.
The safety and efficacy of coadministration with other products for weight loss have not been established.
Compounded tirzepatide has not been studied in patients with a history of pancreatitis.
Note: Compounded medications are not FDA approved and do not have indications for treatment as an FDA approved medication would.
Do not use compounded tirzepatide if:
You can take compounded tirzepatide with or without food. The pre-filled vial is self-administered with a needle and syringe as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your provider, via Hume Care, will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking compounded tirzepatide as prescribed without discussing with your provider first.
Compounded tirzepatide has certain drug interactions. It's important to tell your provider, via Hume Care, all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
Some medications to watch out for include:
It's important to share your entire medical history with your provider, via Hume Care. In particular, tell your provider if you have a past history of:
Tell your provider, via Hume Care, if you are pregnant, planning to become pregnant, or breastfeeding.
If you are pregnant: Compounded tirzepatide should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
If you are a female or male of reproductive potential: Discontinue compounded tirzepatide at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.
If you are breastfeeding: Compounded tirzepatide was found in the milk of lactating rats. Tell your provider, via Hume Care, if you are breastfeeding before you start compounded tirzepatide. At this time, we do not recommend taking compounded tirzepatide if you are breastfeeding or bottle-feeding with breastmilk.
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
The most common side effects are typically mild and usually resolve after the first several weeks of treatment. These can include nausea, vomiting, diarrhea, constipation, abdominal pain, upset stomach, abdominal distension, reflux, headache, fatigue, and dizziness. Swelling, redness, and itchiness at the injection site may occur.
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
Thyroid C-Cell Tumors: In mice and rats, tirzepatide caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether compounded tirzepatide causes thyroid C-cell tumors in humans. Compounded tirzepatide is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Acute Gallbladder Disease: Compounded tirzepatide may cause gallbladder problems, including gallstones. Tell your provider, via Hume Care, right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Low Blood Sugar (Hypoglycemia): Compounded tirzepatide may lower blood glucose. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Acute Kidney Injury: It is important for you to drink plenty of water to help reduce your chance of dehydration.
Serious Allergic Reactions: Stop using compounded tirzepatide right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Diabetic Retinopathy Complications: If you have type 2 diabetes, tell your provider, via Hume Care, right away if you experience changes in vision.
Increase in Heart Rate: Tell your provider, via Hume Care, right away if you have a racing heartbeat while at rest.
Suicidal Behavior and Ideation: Call your provider, via Hume Care, right away if you have any mental changes that are new, worse, or worry you.
Never Share a Vial/Needle/Syringe: Sharing poses a risk of infection.
If you have any current/recent prescriptions for either compounded or brand name weight loss medications, do not take both medications. Notify your provider, via Hume Care, immediately if you have any current or previous prescriptions for compounded or brand name weight loss medications.
Failure to fully disclose your medical history to your provider may result in serious side effects, including death.
Your provider, via Hume Care, will direct you to instructions on how to administer your GLP-1 therapy.
Tell your provider, via Hume Care, if you are taking medicines to treat diabetes including insulin or sulfonylureas which could increase your risk of low blood sugar.
If you take birth control pills by mouth, talk to your provider, via Hume Care, before you use compounded tirzepatide. Your provider may recommend another type of birth control for 4 weeks after you start compounded tirzepatide and for 4 weeks after each increase in your dose of compounded tirzepatide.
Review these questions with your provider, via Hume Care:
Depending on your specific situation, your maintenance dose could be lower than 15 mg once a week. Follow the dosing instructions from your provider, as they may personalize your plan for your individual needs. Oral forms of compounded tirzepatide are typically dosed between 3–6 mg daily. For micro-dosing purposes, compounded tirzepatide dosing starts at 1.25 mg once or twice weekly. Orally micro-dosed compounded tirzepatide is typically at 1.5 mg daily.
Important: Always follow the guidance of your provider, via Hume Care, before starting or adjusting any medication regimen.
1. How does the lab process work? You will receive two separate boxes in the mail. Box 1 should be completed on the morning after delivery. Box 2 should be completed the morning after Box 1 was completed. Both sets of labs should be completed early in the morning while fasting between 7 AM and 10 AM. Both sets of labs should be returned in the mail on the same day as Box 2 was completed.
2. What is testosterone? Testosterone is a hormone primarily produced in the testes in men and, to a lesser extent, in the ovaries in women. It plays a crucial role in the development of male reproductive tissues, secondary sexual characteristics, and overall well-being.
3. How is testosterone administered? Testosterone can be administered through cream (topical), injection (subcutaneously or intramuscularly), or oral dissolvable tablets (ODTs). In most cases, we will be prescribing via the subcutaneous route.
4. Why is it important to move injection sites? Rotating injection sites is essential to prevent tissue damage, irritation, or the development of scar tissue at the injection site.
5. What are the side effects of testosterone? Common side effects may include acne, oily skin, hair loss, increased body hair, mood changes, increased estradiol levels, and testicular atrophy. More serious side effects can include an increase in red blood cell count, sleep apnea, or an enlarged prostate. It's important to monitor these effects with your provider, via Hume Care.
6. What are the benefits of testosterone? Testosterone replacement therapy can provide improved energy levels, increased muscle mass and strength, enhanced libido, improved mood and mental clarity, and better overall well-being.
7. What is the negative feedback loop? When testosterone levels rise due to hormone replacement therapy, the hypothalamus and pituitary gland may reduce the natural production of testosterone. This can lead to a reliance on therapy for maintaining testosterone levels.
8. How does testosterone affect fertility? Testosterone therapy can negatively impact fertility by suppressing the natural production of sperm. This is due to the negative feedback loop, where increased testosterone levels signal the body to reduce the production of LH and FSH, both crucial for sperm production.
9. What is meant by transference? Transference refers to the unintentional transfer of testosterone from one person to another through direct skin contact. Wash hands thoroughly after application and avoid skin contact with others in the area where cream was applied. Testosterone can be transferred by vaporization for 4–6 hours after application — avoid proximity with small children.
10. What increases PSA levels? Elevated PSA levels can be associated with benign prostatic hyperplasia (BPH), prostatitis, recent ejaculation, prostate manipulation, age, testosterone therapy, or prostate cancer. Significant or rapid rises in PSA during testosterone therapy warrant further investigation.
Indications/Use: Primary hypogonadism (congenital or acquired) in men. Hypogonadotropic hypogonadism (congenital or acquired) in men. Delayed puberty in adolescent males (selected cases). Palliative treatment of certain breast cancers in postmenopausal women (rarely used today).
Contraindications: Known or suspected prostate cancer or breast cancer in men. Pregnancy and breastfeeding. Hypersensitivity to testosterone. Serious cardiac, hepatic, or renal disease. Elevated hematocrit (>54%). Untreated/uncontrolled sleep apnea.
Side Effects: Common: acne, oily skin, increased hair growth, gynecomastia, mood changes, hot flashes. Cardiovascular: hypertension. Hematologic: polycythemia. Hepatic: liver dysfunction. Reproductive: reduced sperm production, testicular atrophy, erection changes. Other: poor sleep, sleep apnea worsening, edema, nipple sensitivity.
Warning: Risk of Thyroid C-Cell Tumors
In rats, Zepbound® (tirzepatide) caused thyroid tumors, including thyroid cancer. It is not known if Zepbound® (tirzepatide) will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Do not use Zepbound® (tirzepatide) if you or any of your family have ever had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Zepbound® (tirzepatide) is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with a BMI of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition.
You can take Zepbound® with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your provider, via Hume Care, will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Zepbound® (tirzepatide) as prescribed without discussing with your provider first.
It's important to tell your provider, via Hume Care, all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
It's important to share your entire medical history with your provider, via Hume Care. In particular, tell your provider if you have a past history of: type 1 or type 2 diabetes, thyroid cancer, gastrointestinal disease, pancreatitis, kidney disease, diabetic retinopathy, depression, or suicidal thoughts or behavior.
Tell your provider, via Hume Care, if you are pregnant, planning to become pregnant, or breastfeeding.
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
Thyroid C-Cell Tumors: Tell your provider, via Hume Care, if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Severe Gastrointestinal Disease: Zepbound® is associated with gastrointestinal side effects that can sometimes be severe. It hasn't been studied in patients with severe gastrointestinal disease and isn't recommended in these patients.
Acute Kidney Injury: It is important for you to drink plenty of water to help reduce your chance of dehydration.
Acute Gallbladder Disease: Tell your provider, via Hume Care, right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Low Blood Sugar (Hypoglycemia): Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Diabetic Retinopathy Complications: Tell your provider, via Hume Care, right away if you experience changes in vision.
Suicidal Behavior and Ideation: Call your provider, via Hume Care, right away if you have any mental changes that are new, worse, or worry you.
Never Share a Pen: Pen-sharing poses a risk of infection.
Nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss, gastroesophageal reflux disease (heartburn).
You are encouraged to report negative side effects of prescription products to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. This information is not comprehensive. Please see the full Prescribing Information for complete safety information.
Warning: Risk of Thyroid C-Cell Tumors
In studies with mice and rats, semaglutide caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® (semaglutide) will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Do not use Wegovy® (semaglutide) if you or any of your family have ever had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Wegovy® (semaglutide) is a GLP-1 receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with a BMI of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition.
You can take Wegovy® (semaglutide) with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your provider, via Hume Care, will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Wegovy® (semaglutide) as prescribed without discussing with your provider first.
It's important to tell your provider, via Hume Care, all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
It's important to share your entire medical history with your provider, via Hume Care. In particular, tell your provider if you have a past history of: type 1 or type 2 diabetes, thyroid cancer, pancreatitis, kidney disease, diabetic retinopathy, depression, or suicidal thoughts or behavior.
Tell your provider, via Hume Care, if you are pregnant, planning to become pregnant, or breastfeeding.
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
Thyroid C-Cell Tumors: Tell your provider, via Hume Care, if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Acute Gallbladder Disease: Tell your provider, via Hume Care, right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Low Blood Sugar (Hypoglycemia): Monitor your blood sugar and watch out for signs of too low blood sugar.
Acute Kidney Injury: It is important for you to drink plenty of water to help reduce your chance of dehydration.
Serious Allergic Reactions: Stop using Wegovy® right away if you experience symptoms of a serious allergic reaction.
Diabetic Retinopathy Complications: Tell your provider, via Hume Care, right away if you experience changes in vision.
Increase in Heart Rate: Tell your provider, via Hume Care, right away if you have a racing heartbeat while at rest.
Suicidal Behavior and Ideation: Call your provider, via Hume Care, right away if you have any mental changes that are new, worse, or worry you.
Never Share a Pen: Pen-sharing poses a risk of infection.
Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease.
You are encouraged to report negative side effects of prescription products. Contact Novo Nordisk Inc. at 1-833-934-6891. Contact FDA MedWatch at 1-800-FDA-1088 or visit fda.gov/medwatch. This information is not comprehensive. Please see the full Prescribing Information for complete safety information.
Warning: Risk of Thyroid C-Cell Tumors
Mounjaro® (tirzepatide) injection may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your provider.
Do not use Mounjaro® if you or any of your family have ever had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Mounjaro® (tirzepatide) injection is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).
You can take Mounjaro® (tirzepatide) injection with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your provider, via Hume Care, will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Mounjaro® (tirzepatide) as prescribed without discussing with your provider first.
It's important to tell your provider, via Hume Care, all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
It's important to share your entire medical history with your provider, via Hume Care. In particular, tell your provider if you have a past history of: type 1 or type 2 diabetes, thyroid cancer, gastrointestinal disease, pancreatitis, kidney disease, diabetic retinopathy, depression, or suicidal thoughts or behavior.
Tell your provider, via Hume Care, if you are pregnant, planning to become pregnant, or breastfeeding.
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
Thyroid C-Cell Tumors: Tell your provider, via Hume Care, if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Severe Gastrointestinal Disease: Mounjaro® is associated with gastrointestinal side effects that can sometimes be severe. It hasn't been studied in patients with severe gastrointestinal disease.
Inflammation of the Pancreas (Pancreatitis): Stop using Mounjaro® and call your provider, via Hume Care, right away if you have severe pain in your stomach area that will not go away, with or without vomiting.
Low Blood Sugar (Hypoglycemia): Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness or lightheadedness, sweating, confusion, headache, blurred vision, shakiness, fast heartbeat, or feeling jittery.
Serious Allergic Reactions: Stop using Mounjaro® and get medical help right away if you experience symptoms of a serious allergic reaction.
Kidney Problems (Kidney Failure): It is important for you to drink fluids to help reduce your chance of dehydration.
Gallbladder Problems: Tell your provider, via Hume Care, right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach, fever, yellowing of skin or eyes, or clay-colored stools.
Diabetic Retinopathy Complications: Tell your provider, via Hume Care, right away if you experience changes in vision.
Suicidal Behavior and Ideation: Call your provider, via Hume Care, right away if you have any mental changes that are new, worse, or worry you.
Never Share a Pen: Pen-sharing poses a risk of infection.
Nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss, gastroesophageal reflux disease (heartburn).
You are encouraged to report negative side effects of prescription products to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. This information is not comprehensive. Please see the full Prescribing Information for complete safety information.
Warning: Risk of Thyroid C-Cell Tumors
Ozempic® (semaglutide) may cause serious side effects, including possible thyroid tumors, including cancer. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Ozempic® and medicines that work like Ozempic® caused thyroid tumors, including thyroid cancer. It is not known if Ozempic® will cause thyroid tumors or medullary thyroid carcinoma (MTC) in people.
Do not use Ozempic® if you or any of your family have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used: along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes; and to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.
You can take Ozempic® (semaglutide) with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your provider, via Hume Care, will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Ozempic® (semaglutide) as prescribed without discussing with your provider first.
It's important to tell your provider, via Hume Care, all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
It's important to share your entire medical history with your provider, via Hume Care. In particular, tell your provider if you have a past history of: type 1 or type 2 diabetes, thyroid cancer, gastrointestinal disease, pancreatitis, kidney disease, diabetic retinopathy, depression, or suicidal thoughts or behavior.
Tell your provider, via Hume Care, if you are pregnant, planning to become pregnant, or breastfeeding.
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
Thyroid C-Cell Tumors: Tell your provider, via Hume Care, if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Severe Gastrointestinal Disease: Ozempic® is associated with gastrointestinal side effects that can sometimes be severe. It hasn't been studied in patients with severe gastrointestinal disease.
Inflammation of Your Pancreas (Pancreatitis): Stop using Ozempic® and call your provider, via Hume Care, right away if you have severe pain in your stomach area that will not go away, with or without vomiting.
Low Blood Sugar (Hypoglycemia): Signs and symptoms include dizziness or lightheadedness, blurred vision, anxiety, irritability, sweating, slurred speech, hunger, confusion, shakiness, weakness, headache, fast heartbeat, and feeling jittery.
Kidney Problems (Kidney Failure): It is important for you to drink fluids to help reduce your chance of dehydration.
Serious Allergic Reactions: Stop using Ozempic® and get medical help right away if you have any symptoms of a serious allergic reaction.
Gallbladder Problems: Tell your provider, via Hume Care, right away if you get symptoms of gallbladder problems, including pain in your upper stomach, fever, yellowing of the skin or eyes, or clay-colored stools.
Diabetic Retinopathy Complications: Tell your provider, via Hume Care, right away if you experience changes in vision.
Suicidal Behavior and Ideation: Call your provider, via Hume Care, right away if you have any mental changes that are new, worse, or worry you.
Never Share a Pen: Pen-sharing poses a risk of infection.
Nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss, gastroesophageal reflux disease (heartburn).
You are encouraged to report negative side effects of prescription products. Contact Novo Nordisk Inc. at 1-833-934-6891. Contact FDA MedWatch at 1-800-FDA-1088 or visit fda.gov/medwatch. This information is not comprehensive. Please see the full Prescribing Information for complete safety information.
Compounded semaglutide and compounded tirzepatide are not approved by the FDA. The FDA does not evaluate compounded products for safety, effectiveness, or quality. Compounded medications are permitted to be prescribed under federal law but do not undergo FDA safety, effectiveness, or manufacturing review.
Ozempic®, Wegovy®, Saxenda®, and Victoza® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Byetta® and Bydureon® are registered trademarks of Amylin Pharmaceuticals, Inc.
Hume Care has no affiliation with Novo Nordisk A/S, Eli Lilly and Company, or Amylin Pharmaceuticals, Inc. The compounded products available as part of Hume Care's Weight Loss Program are not manufactured by, nor affiliated with, any of these companies.